Uni Heidelberg: Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy

(marketscreener.com) FPI-2265 positioned to be the first approved PSMA targeted alpha therapy HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into an exclusive...https://www.marketscreener.com/quote/stock/FUSN-PHAR-108985405/news/Fusion-Pharmaceuticals-Enters-into-Exclusive-Worldwide-License-Agreement-with-Heidelberg-University-45972376/?utm_medium=RSS&utm_content=20240216